MIST
Milestone Pharmaceuticals (MIST) displays moderate fundamental health with several notable strengths and weaknesses. Key bullish factors include an interest-coverage ratio of 15.48%, indicating solid interest-payment capacity, and strong revenue momentum with year-over-year growth rates of 78.47% (total operating revenue) and 92.66% (operating revenue). However, the company's days-sales-outstanding at 72.55 days suggests slower receivable collection, and its PB-ROE of 0.1564 implies sub-optimal asset efficiency. Net income-to-revenue is slightly negative at -0.1668, highlighting margin pressure. These mixed signals result in an overall neutral fundamental rating, with a calculated score of 4.54/10. Investors should monitor working-capital management and profitability trends to gauge future fundamental improvement.
Analysis Checks(8/10)
- MIST scores 4.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -271.33% ROE, 0.00% net margin, -2.58 P/E ratio, 7.30 P/B ratio, and 1.25% earnings growth, these metrics solidify its Netural investment rating.
